Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170966 | 0.85 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL8534374 | 0.84 | ALDH1A1 (0.64) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL28993130 | 0.84 | TDP1 (0.58) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL20599922 | 0.81 | ALDH1A1 (0.51) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL2016551 | 0.81 | ALDH1A1 (0.60) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL8784388 | 0.81 | ALDH1A1 (0.60) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL9557590 | 0.81 | ALDH1A1 (0.60) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL18328108 | 0.81 | ALDH1A1 (0.60) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL5370054 | 0.80 | NR4A1 (0.53) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL394346 | 0.79 | ALDH1A1 (0.63) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10806794-B2 | Protease inhibitors having enhanced features | NEKTAR THERAPEUTICS (US) | 2020-10-20 | — | — | US | disclosed |
| US-20180353609-A1 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | NEKTAR THERAPEUTICS | 2018-12-13 | — | — | US | disclosed |
| US-10092656-B2 | Protease inhibitors having enhanced features | NEKTAR THERAPEUTICS (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170028077-A1 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | NEKTAR THERAPEUTICS | 2017-02-02 | — | — | US | disclosed |
| US-20120108501-A1 | Protease Inhibitors | NEKTAR THERAPEUTICS (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2440249-A2 | COVALENT CONJUGATES COMPRISING A PROTEASE INHIBITOR, A WATER-SOLUBLE, NON-PEPTIDIC OLIGOMER AND A LIPOPHILIC MOIETY | Nektar Therapeutics (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20110195940-A1 | Protease Inhibitors Having Enhanced Features | NEKTAR THERAPEUTICS (CA) | 2011-08-11 | — | — | US | disclosed |
| WO-2010144869-A2 | PROTEASE INHIBITORS | NEKTAR THERAPEUTICS (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010033219-A2 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | NEKTAR THERAPEUTICS (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806794-B2 | Protease inhibitors having enhanced features | SERPINB1, SPINT2, TMPRSS15 | ALDH1A1 1697/4885TDP1 989/4885MAPK1 4103/4885 |
| US-10092656-B2 | Protease inhibitors having enhanced features | SERPINB1, SPINT2, TMPRSS15 | ALDH1A1 1697/4885TDP1 989/4885MAPK1 4103/4885 |
| US-20170028077-A1 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | SERPINB1, SPINT2, TMPRSS15 | ALDH1A1 1697/4885TDP1 989/4885MAPK1 4103/4885 |
| US-20110195940-A1 | Protease Inhibitors Having Enhanced Features | CYP3A43, HPN, ANPEP | ALDH1A1 1870/4885TDP1 1783/4885MAPK1 4243/4885 |
| US-20120108501-A1 | Protease Inhibitors | DNPEP, ADAM17, PREP | ALDH1A1 4161/4885TDP1 1780/4885MAPK1 3260/4885 |
| US-20180353609-A1 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | SERPINB1, SPINT2, TMPRSS15 | ALDH1A1 1697/4885TDP1 989/4885MAPK1 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.